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and $658 ± $1808 (presenteeism) per enrollee per year. Morisky-
based adherence was not a signiﬁcant predictor of HRQL or pro-
ductivity in the multivariate models. CONCLUSIONS: Asthma
was associated with HRQL detriments and workplace produc-
tivity losses. Medication adherence continues to be a problem
among asthma patients.
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OBJECTIVES: Recent randomized controlled trials demon-
strated the efﬁcacy of adjuvant chemotherapy for certain patients
with early-stage lung cancer (Winton et al. NEJM 2005) while
the efﬁcacy of adjuvant radiation therapy hasn’t been determined
in clinical trials for these patients. Both treatments have been
used in practice for years and it isn’t clear whether patient sur-
vival beneﬁts are available by expanding treatment rates.
OBJECTIVE: estimate the effectiveness of these treatments in
practice, assess whether survival beneﬁts are available from
expanding treatment rates. It has been suggested that instru-
mental variable estimates on observational data provide such an
interpretation (McClellan et al. JAMA, 1994). METHODS:
Apply instrumental variable (IV) methods to 7614 early-stage
lung cancer patients that received surgery from the SEER-
Medicare databases (1991–1999) to assess the effectiveness of
each adjuvant treatment. Instruments included area-level
Herﬁndahl indices of patient concentration across providers and
area-level treatment rates across time. Covariates included stage,
grade, tumor site, age, gender, and race. RESULTS: Using IV
methods, we found that our instruments explained a statistically
signiﬁcant portion of the variation in adjuvant treatment use.
Using the treatment variation stemming from the instruments,
we found the adjuvant chemotherapy had a positive effect on
three-year patient survival (p < 0.05) while adjuvant radiation
therapy didn’t. Using standard risk-adjustment models leaving
residual confounding in spite of controlling for measured covari-
ates, both adjuvant chemotherapy and adjuvant radiation
therapy had statistically signiﬁcant negative relationships with
three-year patient survival (p < 0.05). CONCLUSION: Using IV
methods provides estimates of effects of treatments in practice,
suggesting survival rates would increase if adjuvant chemother-
apy rates increased for early-stage lung cancer patients. No sur-
vival gains appear available from expanding adjuvant radiation
therapy rates. The IV results contrast the negative “treatment
effects” in standard risk-adjustment models, suggesting that
providers recommended adjuvant treatments to patients with
higher unmeasured severity levels.
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OBJECTIVES: The Healthy People 2010 goal for the nation con-
cerning prostate cancer is to reduce prostate cancer death rate to
28.8 deaths per 100,000 males by 2010. The reported death rate
for African-American men in 2002 was 62.0 per 100,000 males
and for Caucasian men 25.7 per 100,000 males. Based on this
statistic, Caucasian men already fare better than the projected
goal for 2010 while African American (AA) men have a long way
to go to achieve this goal. Prostate cancer education and aware-
ness is very important to eliminate the disparities experienced by
AA men. Thus, the purpose of this study is to evaluate the effec-
tiveness of the prostate cancer education kiosk (PCEK).
METHODS: Participants were adult AAs who are employees of
an HBCU institution. A structured survey instrument assessing
participants’ demographics and prostate cancer knowledge was
employed for the study. Data collection involved three steps: 1)
completion of survey before use of kiosk {pre-test}, 2) use of
kiosk by participants {post-test}, and 3) completion of survey
after use of kiosk {post-test}. RESULTS: Of the 100 participants,
most were men (78%), single (53%), had at least a college degree
(52%), and between 40–49 years (58%). Men’s score on both
the pre-test and post-test knowledge scores were higher than
women. PCEK was found to signiﬁcantly improve participants’
knowledge. The post-test knowledge score of participants
(89.42%) was higher than the pre-test knowledge score of par-
ticipants (67.92%). CONCLUSION: PCEK offers an effective
method to educate AA men about prostate cancer. Future studies
should explore the cost-effectiveness of touch screen computers
such as PCEK in educating the AA community on diverse health
issues.
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OBJECTIVES: Delayed chemotherapy-induced nausea and vom-
iting (CINV) can increase healthcare utilization and decrease
patient quality of life. While reports of delayed CINV range from
40–60% with moderately to highly emetogenic regimens, little
information is available on utilization of care as a result. To
determine the frequency of outpatient service utilization associ-
ated with CINV between 24–120 hours following chemotherapy
administration during cycles 1–5. METHODS: A retrospective
observational design of US Oncology nation-wide iKnowMed
electronic medical records (EMR) was employed. The cohort for
analysis included patients from four practices in separate 
states receiving chemotherapy between August 2004 and 
April 2005. Chemotherapy regimens included one or more of 
the following ﬁve drugs: carboplatin, cisplatin, oxaliplatin, 
doxorubicin, cyclophosphamide. Failure was deﬁned as one 
or more of the following events between 24–120 hours 
following chemotherapy: phone encounters with documentation
of CINV; non-chemotherapy ofﬁce visits for hydration, IV 
anti-emetic administration, and/or documentation of CINV; 
oral anti-emetic orders between 24–120 hours. RESULTS:
A total of 691 patients were identiﬁed as receiving target
chemotherapies during cycles 1–5. Mean (std) age was 61 
(13) years, and 62% were female. Twenty-six percent had 
breast cancer, 26% lung, 10% colorectal, and 8% lymphoma. 
In cycle 1, the rate of failure was 6.7%; in cycle 2, 5.9%; in cycle
3, 5%; in cycle 4, 5.3%; and in cycle 5, 4.0%. All patients
received one or more IV anti-emetic on Day 1 of each cycle.
CONCLUSION: The rates reported in this cohort of patients
from a nation-wide EMR database indicate that while many
patients may experience some degree of CINV during days 2–5
of chemotherapy, only a small percentage receive outpatient
clinic care as a result.
